Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

9 results

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated for the treatment of HIV-1 in adults and adolescents (12 years and older, 35 kg+) as a complete regimen to replace current antiretroviral therapy in those who are virologically suppressed, with no history of treatment failure or known resistance to its components.
    Medication Details

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
    Medication Details
    Drug Interactions

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.
    Medication Details
    Drug Interactions

  • edurant

    (rilpivirine hydrochloride)
    Janssen Products, LP
    EDURANT is indicated for the treatment of HIV-1 in treatment-naïve patients aged 2 and older with specific viral loads. It is also used in combination with cabotegravir for short-term treatment in adults and adolescents who are virologically suppressed and require an oral lead-in or temporary oral therapy.
    Medication Details
    Drug Interactions

  • etravirine

    (etravirine)
    AvKARE
    Etravirine tablets are indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult and pediatric patients aged 6 years and older, when used in combination with other antiretroviral agents.
    Medication Details
    Drug Interactions

  • intelence

    (etravirine)
    Janssen Products LP
    INTELENCE is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults and pediatric patients aged 2 years and older.
    Medication Details
    Drug Interactions

  • juluca

    (dolutegravir sodium and rilpivirine hydrochloride)
    ViiV Healthcare Company
    JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.
    Medication Details
    Drug Interactions

  • odefsey

    (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
    Medication Details
    Drug Interactions

  • pifeltro

    (doravirine)
    Merck Sharp & Dohme LLC
    PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.
    Medication Details
    Drug Interactions